{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decadron%C2%AE&page=2", "query": { "intervention": "Decadron®", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decadron%C2%AE&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T13:16:46.308Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06533748", "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Inotuzumab", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "IT MHA", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "6-Mercaptopurine", "type": "DRUG" }, { "name": "Calaspargase", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 128, "start_date": "2025-01-23", "completion_date": "2034-05", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 3, "location_summary": "Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533748" }, { "nct_id": "NCT01239797", "title": "Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Dexamethasone (Oral)", "type": "DRUG" }, { "name": "Dexamethasone (IV)", "type": "DRUG" }, { "name": "Elotuzumab (BMS-901608; HuLuc63)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 646, "start_date": "2011-06-20", "completion_date": "2021-04-21", "has_results": true, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 63, "location_summary": "Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239797" }, { "nct_id": "NCT06207305", "title": "A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Appendiceal Adenocarcinoma", "Intraperitoneal Paclitaxel" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2024-01-30", "completion_date": "2028-01-02", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06207305" }, { "nct_id": "NCT01847001", "title": "Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Malignant Neoplasm", "Breast Cancer" ], "interventions": [ { "name": "Propranolol", "type": "DRUG" }, { "name": "DOT imaging", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Premedication", "type": "DRUG" }, { "name": "Anti-nausea therapy", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2012-10", "completion_date": "2019-10-16", "has_results": true, "last_update_posted_date": "2021-09-10", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847001" }, { "nct_id": "NCT00413959", "title": "VELCADE,Rituximab,Cyclophosphamide and Decadron", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell" ], "interventions": [ { "name": "VELCADE®", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decadron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 12, "start_date": "2006-08", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 2, "location_summary": "Niles, Illinois • Park Ridge, Illinois", "locations": [ { "city": "Niles", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413959" }, { "nct_id": "NCT05697809", "title": "Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "OXU-001", "type": "DRUG" }, { "name": "Semi-automated suprachoroidal illuminated microcatheter", "type": "DEVICE" }, { "name": "Ozurdex® Ophthalmic Intravitreal Implant", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Oxular Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-08-07", "completion_date": "2024-12-05", "has_results": true, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Oak Forest", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05697809" }, { "nct_id": "NCT01222260", "title": "Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-01", "completion_date": "2019-07-03", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222260" }, { "nct_id": "NCT06988488", "title": "A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2025-10-07", "completion_date": "2027-06-03", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 4, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06988488" }, { "nct_id": "NCT04094961", "title": "Ixazomib + Pomalidomide + Dexamethasone In MM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Omar Nadeem, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2019-09-18", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04094961" }, { "nct_id": "NCT00525447", "title": "Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "SGN-40", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2007-08", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2014-10-09", "last_synced_at": "2026-09-28T13:16:46.308Z", "location_count": 9, "location_summary": "Denver, Colorado • Tampa, Florida • Boston, Massachusetts + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525447" } ] }